AUTHORS
Jieya Luo, Xinhui Zheng2, Wenhao Wang3, Jingqi Li, N/A4, Xin Chen5, Erlie Jiang, MD6
AFFILIATIONS
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Tianjin, China, Tianjin Institutes of Health Science, Tianjin, China
ABSTRACT
Background
Systemic corticosteroids remain the standard first-line therapy for gastrointestinal acute graft-versus-host disease (GI-aGVHD), but incomplete intestinal responses and infection risk from prolonged high-dose exposure highlight the need for organ-targeted adjunctive strategies. Vedolizumab (VDZ), a gut-selective anti-α4β7 integrin antibody, inhibits lymphocyte trafficking to the intestine. We evaluated the efficacy, steroid-sparing effect, and safety of early VDZ combined with first-line therapy for GI-aGVHD.
Methods
This study used 1:2 propensity score matching to compare patients who received VDZ within 0–2 days after aGVHD onset as part of first-line therapy (VDZ group, n=33) with those receiving best available therapy without VDZ (non-VDZ group, n=60). The propensity score model included GI-aGVHD severity at treatment initiation, maximum GI-aGVHD grade, baseline corticosteroid dose, and first-line regimen. All response outcomes were assessed from the date of aGVHD onset. The primary endpoint was the day 28 overall response rate (ORR); secondary endpoints included ORR at predefined time points, corticosteroid tapering, infections, and hematologic adverse events.
Results
Baseline characteristics were generally balanced, with approximately 75% of patients reaching grade III–IV aGVHD at maximum severity. Day 28 ORR was comparable between the VDZ and non-VDZ groups (45.5% vs. 35.0%, P=0.322), with no significant differences in day 7 ORR (12.1% vs. 5.0%, P=0.240), day 14 ORR (21.2% vs. 20.0%, P=0.890), day 56 ORR (51.5% vs. 60.0%, P=0.429), or overall ORR (60.6% vs. 71.7%, P=0.275). Median time to complete response was numerically shorter in the VDZ group (27 vs. 33 days, P=0.128).
Subgroup analyses showed no statistically significant difference in day 28 ORR between the VDZ and non-VDZ groups among patients with grade I gastrointestinal involvement at onset (54.2% vs. 34.0%, P=0.103) or among those with grade II–IV gastrointestinal involvement (22.2% vs. 38.5%, P=0.648). Similarly, no significant difference was observed when patients were stratified by overall aGVHD severity, with day 28 ORR of 71.4% versus 61.5% in grade II–III aGVHD (P=0.730) and 26.3% versus 14.7% in grade IV aGVHD (P=0.465). In the corticosteroid-only first-line backbone subgroup, VDZ was associated with a higher ORR that did not reach statistical significance (75.0% vs. 18.2%, P=0.077). Notably, among patients requiring ≥3 non-corticosteroid therapeutic agents, VDZ was associated with a significantly higher day 28 ORR (38.1% vs. 11.5%, P=0.043). Firth-penalized multivariable logistic regression further suggested greater VDZ benefit in patients with initial grade I intestinal involvement (OR=0.06, P=0.041) or isolated gastrointestinal involvement (OR=0.06, P=0.011), whereas concomitant infection at aGVHD treatment was associated with overall treatment failure (OR=14.38, P=0.027).
Although VDZ did not significantly improve ORR, it was associated with faster corticosteroid tapering. Generalized additive mixed model analysis showed a more rapid decline in corticosteroid dose in the VDZ group (P=0.024), mainly during days 0-14 (P=0.025). Consistently, more patients receiving VDZ achieved a ≥50% corticosteroid dose reduction within 14 days (51.5% vs. 28.3%, P=0.026), whereas day 28 tapering success was comparable between groups (60.6% vs. 58.3%, P=0.833). Fecal calprotectin, an intestinal inflammatory marker, declined more rapidly in the VDZ group during days 9-28 (P=0.009). VDZ was not associated with an increased risk of infectious events or grade 3-4 hematologic adverse events. Within 4 months after treatment, the incidences of cytomegalovirus reactivation (9.1% vs. 15.0%, P=0.529), Epstein-Barr virus reactivation (15.2% vs. 28.3%, P=0.152), pulmonary infection (39.4% vs. 46.7%, P=0.449), and severe infection (24.2% vs. 28.3%, P=0.670) were comparable between the VDZ and non-VDZ groups.
Conclusion
Early VDZ combined with first-line therapy did not significantly improve the day 28 ORR in GI-aGVHD. However, it may facilitate earlier intestinal improvement and faster corticosteroid tapering, particularly in patients with milder initial gastrointestinal involvement or isolated gastrointestinal disease, without increasing infectious or hematologic toxicity.
DISCLOSURES
Jieya Luo: No relevant conflicts of interest to declare.